Compare MPT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPT | BEAM |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | 121 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | N/A | 2019 |
| Metric | MPT | BEAM |
|---|---|---|
| Price | $5.20 | $32.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $5.00 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 4.8M | 2.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.91 | $33.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $4.51 | $15.60 |
| 52 Week High | $6.47 | $36.44 |
| Indicator | MPT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 59.45 |
| Support Level | $4.86 | $22.59 |
| Resistance Level | $6.47 | $32.74 |
| Average True Range (ATR) | 0.17 | 2.20 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 65.84 | 91.84 |
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.